

ITL BioMedical Announces Distribution Agreement with bioMérieux Canada

[ITL BioMedical](#), a division of ITL (ASX: ITD) that sets industry standards for the innovative design and production of biological sampling systems for human and animal use, is pleased to announce it has signed a five year distribution agreement, with possible ongoing renewals, for its Safety SubCulture Unit (SCU) with [bioMérieux Canada Inc.](#) The total estimated number of subculture procedures performed in the Canadian market per year is between 700,000 to one million.

bioMérieux Canada Inc. is a subsidiary of bioMérieux (Euronext: BIM), a world leader *in vitro* diagnostics for more than 50 years. bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety.

ITL BioMedical has partnered with bioMérieux for over five years for the supply of bacterial screening ancillaries as well as the SCU in the United Kingdom, and has recently signed a global distribution agreement for ITL's SampLok® Sampling System (SSK), one of these ancillaries.

SCU is a highly innovative state of the art product that is utilized in laboratories to safely transfer samples that have tested positive for bacteria for further testing. The design incorporates process efficiencies, safety in reducing potential for needlestick injuries, and reduced biohazard exposure to potential sprays and aerosols, among other benefits. The device is compatible with bacterial culture bottles, offering two methods for sample transfer, both a drip method onto a culture plate as well as a controlled measurement of sample volume into a syringe.

“This distribution contract with bioMérieux Canada Inc. is yet another excellent achievement by ITL BioMedical this year,” commented Bill Mobbs, Executive Chairman of ITL. “bioMérieux is a highly respected company and its global presence will facilitate the expansion of SCU sales.”

Bill Mobbs

Executive Chairman

ITL Limited ABN 16 088 212 088
Unit 1, 63 Wells Road
Chelsea Heights, Victoria, 3196

ITL is an innovative diversified medical technology company that creates and manufactures leading edge medical devices for Operating Theatres, Bloodbanks and laboratories.

ITL's patented medical devices are sold in over 50 countries and protect healthcare workers in millions of procedures annually.

ITL's wholly owned subsidiary MyHealthTest creates and markets highly innovative direct to consumer pathology testing for major chronic diseases.



Ranked 16th most Innovative Company by the AFR
Innovative Companies Awards

Australian Securities Exchange
Code: ITD

Ordinary Shares
95,928,314

Board of Directors

Bill Mobbs	Executive Chairman
Mark Peatey	Non-executive Director
Andrew Turnbull	Non-executive Director

Trevor Doolan	Chief Financial Officer & Company Secretary
---------------	--

ITL Contact
Trevor Doolan Company Secretary
Phone: +61 3 8773 3050
Email: info@itl-limited.com

www.itl-limited.com

Media
Ben Knowles Walbrook IR
Phone: +61 426 277 760

Email: ben.knowles@walbrookir.com.au



ASX Announcement 5 December 2016

About ITL BioMedical – ITLBioMedical.com

ITL BioMedical is a division of ITL that sets industry standards for the innovative design and production of biological sampling systems for human and animal use. The Division's patented medical devices focus on safety and process efficiency for end-users and their blood donors and patients in healthcare markets worldwide. For more information visit ITLBioMedical.com.